Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
November 14th, 2018 by Amanda Poissonnier
Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation, Published online: 14 November 2018; doi:10.1038/s41589-018-0162-9
The HIV protease inhibitor ritonavir targets the calcium-inducing domain (CID) of CD95 to block interactions with PLCγ1. Peptidomimetics targeting the CD95 CID prevents accumulation of inflammatory Th17 cells observed in systemic lupus erythematosus.